Psychedelics Afghanistan Veteran gets Health Canada approval for psilocybin treatment from Apex Labs Kelsi Sheren said that other treatment methods for her PTSD and depression were ineffective Rowan DunneSeptember 28, 2023
News Antidepressants enhance DMT efficacy in patients with severe depression: Small Pharma study The study found that 100 per cent of patients were responsive and 92 per cent went into remission Natalia Buendia CalvilloSeptember 27, 2023
Psychedelics California startup Tactogen gets U.S. patent for MDMA derivatives The company focuses on developing novel psychoactive drugs with more gentle effects Rowan DunneSeptember 27, 2023
Psychedelics Billionaire Steve Cohen’s Point 72 hedge fund takes 8.1% stake in Cybin It now has 19 million shares of the psychedelic drug developer, the firm's first investment in a public entity of this variety Rowan DunneSeptember 19, 2023
News MDMA-assisted therapy significantly reduces moderate to severe PTSD symptoms The study findings represent the culmination of more than two decades of dedicated research efforts Natalia Buendia CalvilloSeptember 15, 2023
Psychedelics Sweden’s Norrsken Foundation launches $4.4M psychedelics mental health initiative Funds will be used to study psilocybin and MDMA-assisted therapy; non-profit says Sweden needs to 'catch up' in this area of research Rowan DunneSeptember 14, 2023
News Silo Pharma to test a novel experimental intranasal formulation for PTSD Silo's SPC-15 was developed in collaboration with Columbia University Natalia Buendia CalvilloSeptember 13, 2023
News Lucy Scientific acquires BlueSky Wellness portfolio of brands Lucy expects to complete the acquisition within 90 days Natalia Buendia CalvilloSeptember 12, 2023
Psychedelics AI shows potential for predicting psilocybin therapy outcomes: COMPASS study The paper in the journal Psychopharmacology concluded that a machine learning algorithm could predict treatment efficacy Rowan DunneSeptember 8, 2023
News Clearmind to collaborate with Johns Hopkins University to study promising psychedelic treatment for alcohol use disorder Johns Hopkins University School of Medicine is the second U.S. clinical site to join Clearmind's trial, following Yale School of Medicine's psychiatry department Natalia Buendia CalvilloSeptember 6, 2023